Bluebird bio warns of potential bankruptcy as buyout faces another delay
Bluebird bio shareholders have dragged their feet in tendering shares as part of the company's sale process, prompting buyers Carlyle and SK Capital to extend their offer once again.
Bluebird bio shareholders have dragged their feet in tendering shares as part of the company's sale process, prompting buyers Carlyle and SK Capital to extend their offer once again.
